Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA Jr.

J Natl Cancer Inst. 2006 Apr 19;98(8):529-34.

PMID:
16622122
2.

Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians.

Coley CM, Barry MJ, Fleming C, Mulley AG.

Ann Intern Med. 1997 Mar 1;126(5):394-406. Review.

PMID:
9054286
3.

Population screening for prostate cancer and emerging concepts for young men.

Moul JW.

Clin Prostate Cancer. 2003 Sep;2(2):87-97. Review.

PMID:
15040869
5.

Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.

Lim LS, Sherin K; ACPM Prevention Practice Committee.

Am J Prev Med. 2008 Feb;34(2):164-70. doi: 10.1016/j.amepre.2007.10.003. Review. Erratum in: Am J Prev Med. 2008 May;34(5):454.

PMID:
18201648
6.

Genetic counseling for prostate cancer risk.

Nieder AM, Taneja SS, Zeegers MP, Ostrer H.

Clin Genet. 2003 Mar;63(3):169-76. Review.

PMID:
12694223
7.

Prevention of prostate cancer with finasteride: US/European perspective.

Thompson IM, Klein EA, Lippman SM, Coltman CA, Djavan B.

Eur Urol. 2003 Dec;44(6):650-5. Review.

PMID:
14644115
8.

[Diagnosis based on prostate needle biopsy: inadequate correlation between pathologic results and clinical course for individual prognosis].

van der Kwast TH, Hoedemaeker RF, Schröder FH.

Ned Tijdschr Geneeskd. 2005 Apr 30;149(18):972-6. Review. Dutch.

PMID:
15903037
9.

Minority issues in prostate disease.

French DB, Jones LA.

Med Clin North Am. 2005 Jul;89(4):805-16. Review.

PMID:
15925651
10.

Racial differences in adenocarcinoma of the prostate in North American men.

Morton RA Jr.

Urology. 1994 Nov;44(5):637-45. Review.

PMID:
7526522
11.

Risk of developing prostate cancer in the future: overview of prognostic biomarkers.

Fleshner NE, Lawrentschuk N.

Urology. 2009 May;73(5 Suppl):S21-7. doi: 10.1016/j.urology.2009.02.022. Review. Erratum in: Urology. 2010 Sep;76(3):771.

PMID:
19375623
12.

Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Schröder FH.

Can J Urol. 2005 Feb;12 Suppl 1:2-6; discussion 92-3. Review.

PMID:
15780157
13.

The status of prostate cancer early detection.

Mettlin C.

Cancer. 1993 Aug 1;72(3 Suppl):1050-5. Review.

14.

Epidemiology of prostate cancer.

Crawford ED.

Urology. 2003 Dec 22;62(6 Suppl 1):3-12. Review.

PMID:
14706503
16.

Five-alpha-reductase Inhibitors for prostate cancer prevention.

Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Kramer BS.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD007091. doi: 10.1002/14651858.CD007091. Review.

PMID:
18425978
17.

Defining high-risk prostate cancer: current status.

Fleshner N.

Can J Urol. 2005 Feb;12 Suppl 1:14-7; discussion 94-6. Review.

PMID:
15780159
18.
19.

Social ecological predictors of prostate-specific antigen blood test and digital rectal examination in black American men.

Woods VD, Montgomery SB, Herring RP, Gardner RW, Stokols D.

J Natl Med Assoc. 2006 Apr;98(4):492-504. Review.

20.

[General features and strategy in the diagnosis of prostatic carcinoma].

Stoffel F, Gasser TC.

Ann Ital Chir. 1999 Sep-Oct;70(5):657-63. Review. Italian.

PMID:
10692784

Supplemental Content

Support Center